Pharma BD Deal Intelligence
Genentech, Inc. (Roche Group) / MaxCyte, Inc.
2026 · Licensing/Option · Complete
MaxCyte granted Genentech, a member of the Roche Group, a multi-platform technology license covering the ExPERT GTx platform and additional MaxCyte cell-engineering technologies for use across select research, clinical development and cGMP manufacturing workflows supporting multiple Genentech ex vivo cell therapy programs. Financial terms were not disclosed.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jul 21, 2026
- Deal type Licensing/Option
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · Genentech, Inc. (Roche Group) deals